Dupilumab in Atopic Dermatitis – Rate of Poor Responders and Potential Risk Factors from the TREATgermany Registry
Year: 2026
Type: article
Study design: Observational Study
Abstract: A distinct proportion of patients with atopic dermatitis and dupilumab treatment does not reach the primary endpoint of an eczema area severity index (EASI)-75 or investigator global assessment 0/1 after 16 weeks. Little is known about poor responders to dupilumab in real life scenarios. The study objective was to identify the percentage and characteristics of patients with insufficient treatment response to dupilumab based on "TREATgermany" registry data from dermatological routine care. Between 06/2016 and 12/2024, 476 patients matched the study criteria. In total, 4% of patients (n=19) were identified as dupilumab poor responders, i.e. reduction in EASI ≤40% at the 1st follow-up visit after 8 to 20 weeks and a consecutive 2nd follow-up visit up to 52 weeks of treatment. 44% (n=209) were classified as stable responders, i.e. decrease in EASI≥75% at both follow-up visits. Poor responders were significantly more often male, more frequently exhibited smoking, arterial hypertension and a higher body mass index. This TREATgermany data analysis demonstrates a proportion of 4% dupilumab poor responders within the first year of treatment. Male sex, smoking, arterial hypertension and increased body mass index were identified as potential risk factors. Further translational research is needed to confirm these clinical findings.
Source: Acta Dermato Venereologica
Authors: Annice Heratizadeh, Joëlle Naim, Barbara Kind, Katharina Loennecke, Sascha Fischer, Tatjana Honstein, Stephan Traidl, Eva Moennig, Thomas Birkner, Inken Harder, Caroline Mann, Thomas Schaefer, Susanne Abraham, Matthias Augustin, Jutta Ramaker-Brunke, Andreas Pinter, Kathrin Meinhardt, Sven Quist, Sabine Anders, Beate Schwarz, Michael Schulz-Kiesow, Sabine Steinke, Nicole Adler, Christiane Handrick, Knut Schäkel, Michael Sticherling, Anne Bong, Felix Jacobs, Bernd Großmann, Maren Stahl, Carl-Philipp Buerkle, Hannah Gorriahn-Maiterth, Tilo Biedermann, Stephan Weidinger, Jochen Schmitt, Thomas Werfel
Institutions: Medizinische Hochschule Hannover, University Hospital Carl Gustav Carus, Zentrum für Evidenzbasierte Gesundheitsversorgung, Technische Universität Dresden, University Hospital Schleswig-Holstein, University Medical Center of the Johannes Gutenberg University Mainz, Universität Hamburg, University Medical Center Hamburg-Eppendorf, University Hospital Frankfurt, University Hospital Heidelberg, Universitätsklinikum Erlangen, Jungheinrich (Germany), Empolis (Germany), Technical University of Munich
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,725
Funders: Sanofi, Regeneron Pharmaceuticals, Galderma
OpenAlex ID: W7225320587